Compare Celestica Inc (CLS) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celestica Inc vs McKesson Corporation — how do they compare? Celestica Inc trades at $329.87 (market cap $39.28B), while McKesson Corporation trades at $806.22 (market cap $94.06B). The key difference: McKesson Corporation is far larger — about 2.4× Celestica Inc's market cap, and McKesson Corporation pays a 0.41% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| CLS | MCK | |
|---|---|---|
Market Cap | $39.28B | $94.06B |
Sector | Technology | Health |
52-Week High | $472.40 | $995.69 |
52-Week Low | $156.91 | $659.01 |
Enterprise Value | $39.68B | $98.70B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celestica (CLS) trades at $345.18, down 4.08% over 24 hours, with technical indicators showing a bearish trend near key support at $339. The company demonstrates strong fundamentals with Q1 2026 EPS of $2.16 beating estimates, revenue growth accelerating to 55.55% YoY, and a robust ROE of 52.45%. Recent leadership appointments and raised FY2026 revenue guidance to $19 billion reflect operational momentum amid AI and data center demand tailwinds.
Wall Street maintains a bullish outlook with 63% buy ratings and a $440.10 consensus price target, implying 27% upside. Key risks include competitive pressures in the EMS sector and execution challenges in margin expansion. The stock's high P/E of 41.82 warrants monitoring, but earnings beats and institutional confidence support a positive investment case pending Q2 results on July 28, 2026.
McKesson (MCK) trades at $812.28, up 0.78% with a bullish technical signal. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations. Revenue grew to $359.05B in 2025, though net margins remain thin at 1.18%. Analysts maintain strong buy consensus (80%) with a $932.83 price target. Recent news highlights growth in specialty pharma and oncology services, supporting positive momentum.
Outlook remains positive driven by earnings strength and sector tailwinds, but risks include policy changes and high liabilities. The stock offers value with a P/E of 21.16 and P/S of 0.25, though investors should monitor debt levels and execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
